Table 1 Clinicopathological characteristics and surgical short-term outcomes according to background of HCC
Variable | HBV-HCC (n = 149) | HCV-HCC (n = 424) | non-B non-C-HCC (n = 216) | P value | |
|---|---|---|---|---|---|
HBV vs. non-B non-C | HCV vs. non-B non-C | ||||
Host-related factors | |||||
Age, years | 60 (16–83) | 69 (39–85) | 71 (33–89) | < 0.001 | 0.032 |
Sex, male/female | 114/35 | 306/118 | 173/43 | 0.413 | 0.027 |
BMI, kg/m2 | 23 (16–35) | 22 (16–35) | 23 (13–45) | 0.354 | < 0.001 |
HT | 30 (22.7) | 122 (36.3) | 56 (49.1) | < 0.001 | 0.016 |
DM | 17 (11.4) | 88 (20.8) | 102 (47.2) | < 0.001 | < 0.001 |
Dyslipidemia | 12 (9.1) | 57 (16.9) | 34 (15.7) | 0.192 | 0.781 |
Heavy drinking | 68 (45.6) | 164 (38.7) | 134 (62.0) | 0.002 | < 0.001 |
Smoking | 81 (54.4) | 211 (49.8) | 139 (64.4) | 0.066 | < 0.001 |
Serum Alb, g/dl | 4.0 (2.4–4.9) | 3.8 (2.2–5.1) | 3.9 (2.8–5.2) | 0.875 | < 0.001 |
Serum AST, IU/L | 37 (16–178) | 46 (6–293) | 33 (10–142) | 0.064 | < 0.001 |
Serum ALT, IU/L | 39 (9–134) | 43 (5–420) | 34 (8–215) | 0.016 | < 0.001 |
Serum T.bil, mg/dl | 0.9 (0.4–1.9) | 0.8 (0.2–2.7) | 0.8 (0.3–2.8) | 0.048 | 0.565 |
Serum Cre, mg/dl | 0.74 (0.4–10.4) | 0.75 (0.1–9.88) | 0.8 (0.4–11.6) | 0.015 | 0.005 |
Prothrombin time, % | 82 (26–116) | 88 (46–125) | 89 (32–130) | < 0.001 | 0.222 |
Platelet count, 104/ml | 13.9 (3.9–50.4) | 12.1 (3.0–53.1) | 16.2 (4.1–41.4) | 0.001 | < 0.001 |
Fib 4 index | 2.5 (0.3–14.3) | 3.9 (0.9–16.4) | 2.6 (0.4–14.5) | 0.975 | < 0.001 |
ICGR15, % | 13 (2–47) | 18 (4–90) | 12 (3–89) | 0.773 | < 0.001 |
AFP, ng/ml | 22 (0.7–999,999) | 24 (0.3–184,000) | 89 (0–9,099,400) | < 0.001 | < 0.001 |
DCP, mAU/ml | 60 (10.0–10,300) | 60 (8.0–211,120) | 92 (10–11,013) | 0.046 | 0.002 |
Child–Pugh classification | 0.007 | 0.004 | |||
A | 139 (93.3) | 399 (94.1) | 213 (98.6) | ||
B | 10 (6.7) | 25 (5.9) | 3 (1.4) | ||
Tumor factors | |||||
Primary tumor | 0.993 | 0.171 | |||
T1-2 | 138 (92.6) | 404 (95.3) | 200 (92.6) | ||
T3-4 | 11 (7.4) | 20 (4.7) | 16 (7.4) | ||
Tumor size, cm | 3.0 (1.1–27) | 2.8 (0.9–15.5) | 4.0 (0.5–20.0) | < 0.001 | < 0.001 |
Tumor number | 0.929 | 0.137 | |||
Single | 116 (77.9) | 309 (72.9) | 169 (78.2) | ||
Multiple | 33 (22.1) | 115 (27.1) | 47 (21.8) | ||
Fc-inf | 82 (55.0) | 242 (57.1) | 123 (56.9) | 0.718 | 0.975 |
Portal vein invasion | 53 (35.6) | 124 (29.3) | 66 (30.6) | 0.316 | 0.732 |
Hepatic vein invasion | 16 (10.7) | 36 (8.5) | 38 (17.6) | 0.065 | 0.001 |
Bile duct invasion | 3 (2.0) | 7 (1.7) | 3 (1.4) | 0.647 | 0.799 |
Intrahepatic metastasis | 16 (10.7) | 42 (9.9) | 27 (12.5) | 0.606 | 0.322 |
Edmondson-Steiner grade | 0.384 | 0.717 | |||
1 or 2 | 113 (75.8) | 310 (73.1) | 155 (71.8) | ||
3 or 4 | 36 (24.2) | 114 (26.9) | 61 (28.2) | ||
Fibrosis stagea | 0.002 | < 0.001 | |||
F0-3 | 87 (58.4) | 246 (58.0) | 159 (73.6) | ||
F4 | 62 (41.6) | 178 (42.0) | 57 (26.4) | ||
Surgical factors | |||||
Operation time, min | 344 (145–712) | 340 (100–990) | 383 (82–1045) | 0.018 | < 0.001 |
Blood loss, mL | 420 (0–4770) | 450 (0–3960) | 450 (0–6600) | 0.314 | 0.702 |
Intraoperative PRBC | 10 (6.7) | 36 (8.5) | 24 (11.1) | 0.148 | 0.288 |
Resected liver weight, g | 110 (4–3620) | 87 (4–1800) | 162 (2–2270) | 0.044 | < 0.001 |
Procedure | 0.226 | < 0.001 | |||
Anatomical resection | 83 (55.7) | 195 (46.0) | 134 (62.1) | ||
Non-anatomical resection | 66 (44.3) | 229 (54.0) | 82 (37.9) | ||
Surgical margin, mm | 3.0 (0.0–35.0) | 2.0 (0.0–44.0) | 2.5 (0.0–60.0) | 0.629 | 0.509 |
Total bilirubin max, mg/dl | 1.5 (0.7–5.3) | 1.4 (0.5–18.4) | 1.5 (0.6–36.6) | 0.662 | 0.038 |
PHLF | 0.160 | < 0.001 | |||
Grade A | 12 (7.9) | 13 (8.6) | 25 (16.6) | ||
Grade B | 17 (11.3) | 62 (41.1) | 19 (12.6) | ||
Major complicationb | 23 (15.4) | 95 (22.4) | 45 (20.8) | 0.189 | 0.648 |
Postoperative hospital stay, days | 22 (5–117) | 24 (5–111) | 17 (4–107) | < 0.001 | < 0.001 |
Mortality | 0 (0.0) | 3 (0.7) | 1 (0.4) | 0.999 | 0.998 |